Access Options
The BioCompound can be followed in five ways: public access, the VRTX demonstration, standalone company deep dives, Sequential Access subscription, and Full Library Access subscription.
The difference is not hype, timing, or trading access. The difference is analytical depth and when you see the research.
Public Access
Public visitors can read the public website archive.
Included
- One company revealed per month
- Short public posts for released companies
- Framework explainers
- Public archive
Experience
Public access shows what has entered the public catalogue. It does not include the full deep dives, subscriber memos, hidden names, allocation logic, or paid archive access.
VRTX Demonstration Request
Public visitors can request the VRTX demonstration deep dive by email.
The VRTX demonstration shows the BioCompound analytical format on one benchmark company. It excludes allocation percentage, model dollar amount, company-level monitoring triggers, cross-sleeve comparison, portfolio context, and other current holdings.
Standalone Deep Dive — $45
A standalone deep dive is a one-time purchase for a publicly released company.
Included:
- Full Framework methodology document
- Full written deep dive per company in the current public archive
- Framework application to one company
- Sleeve rationale
- Named risks
- Disease-area and competitive context
- $45 credit toward Sequential Access if upgraded within 30 days
Standalone purchases do not include monthly memos, allocation percentages, cross-sleeve synthesis, access to other names, or pre-release company access.
Sequential Access — $249/year
Sequential Access is for readers who want each full deep dive as it enters the public record.
Included
- One full deep dive each month as that company enters the public catalogue
- Monthly research memo scoped to publicly released names
- Sleeve reassessments on publicly released names
- Failure analyses on publicly released names
- Archive of all released deep dives during the subscription period
Sequential Access does not include names that have not yet entered the public catalogue.
Full Library Access — $448/year
Full Library Access is for readers who want immediate access to the entire annual 12-company BioSleeve library.
Included
- Immediate access to all twelve current-cycle deep dives
- Names not yet publicly released
- Monthly research memo covering all names in the model
- Sleeve reassessments on all model names
- Failure analyses on all model names
- Full archive access for the duration of the subscription
What Paid Access Is Not
Paid access is not a signal service, a trade log, a managed account, or personalized investment advice.
The product is research. It documents how one framework evaluates publicly traded biotech companies over time.
Why This Matters
The value of the framework is not a single company. It is how companies are grouped, how they move between sleeves, and how conditions are defined. Premium gives access to that structure immediately.